利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.014 秒)

    MONOCLONAL ANTIBODY PAM4 AND ITS USE FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER
    1.
    发明公开
    MONOCLONAL ANTIBODY PAM4 AND ITS USE FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER 有权
    单克隆抗体PAM4及其用途的诊断和胰腺癌的治疗

    公开(公告)号：EP1521775A1

    公开(公告)日：2005-04-13

    申请号：EP03760086.3

    申请日：2003-06-16

    申请人： Immunomedics, Inc.

    发明人： GOLD, David, V. ,  GOLDENBERG, David, M. ,  HANSEN, Hans

    IPC分类号： C07K16/18

    CPC分类号： C07K16/44 ,  A61K51/1057 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565

    摘要： This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functionalantibodies in a host. More specifically, the present invention relates to the tumor-­associated antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

    ANTI-MUCIN ANTIBODIES FOR EARLY DETECTION AND TREAMENT OF PANCREATIC CANCER
    3.
    发明公开
    ANTI-MUCIN ANTIBODIES FOR EARLY DETECTION AND TREAMENT OF PANCREATIC CANCER 审中-公开
    抗胰蛋白酶抗体用于胰腺癌早期检测和治疗

    公开(公告)号：EP2981829A1

    公开(公告)日：2016-02-10

    申请号：EP14778990.3

    申请日：2014-04-01

    申请人： Immunomedics, Inc.

    发明人： LIU, Donglin ,  GOLD, David, V. ,  CHANG, Chien-Hsing ,  GOVINDAN, Serengulam, V. ,  GOLDENBERG, David, M.

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57438 ,  A61K2039/505 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  G01N2333/4725

    摘要： Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

    摘要翻译： 本文描述了抗胰腺癌抗体或其片段（例如鼠，嵌合，人源化或人PAM4抗体）的组合物和使用方法。 这些抗体显示出新的和有用的诊断特征，例如与胰腺癌和其他癌症的高特异性结合，但不与正常或良性胰腺组织结合并与高百分比的早期胰腺癌结合。 优选地，抗体与位于MUC5ac的第二至第四富半胱氨酸结构域（氨基酸残基1575-2052）内的表位结合，并用于检测和诊断早期胰腺癌。 在更优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定检测血清中早期胰腺癌的标志物。 最优选地，在免疫测定之前用有机相如丁醇提取血清。